Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK exclusively for treating type 2 diabetes mellitus in adults. Fibromyalgia, a chronic pain condition affecting 2–4% of the UK population, is characterised by widespread musculoskeletal pain, fatigue, and sleep disturbances. Despite growing interest in potential off-label uses of Ozempic, there is currently no clinical evidence or licensed indication supporting its use for fibromyalgia. This article examines the mechanisms of Ozempic, explores current evidence-based fibromyalgia treatments recommended by NICE, and clarifies why Ozempic is not an appropriate treatment option for this chronic pain condition.

What Is Ozempic and How Does It Work?

Ozempic (semaglutide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. Ozempic is administered as a once-weekly subcutaneous injection and works by mimicking the action of the naturally occurring hormone GLP-1, which plays a crucial role in regulating blood glucose levels.

The mechanism of action of Ozempic involves several physiological processes. Firstly, it stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is released only when blood glucose levels are elevated. Secondly, it suppresses the release of glucagon, a hormone that raises blood glucose levels. Thirdly, Ozempic slows gastric emptying, which helps to reduce post-meal blood glucose spikes. Additionally, it acts on appetite centres in the brain, leading to reduced food intake and, consequently, weight loss in many patients.

In the UK, Ozempic is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available on NHS prescription for eligible patients with type 2 diabetes who meet specific criteria outlined in NICE Guideline NG28. Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain, particularly during the initial titration phase. Other important safety considerations include risk of hypoglycaemia when combined with insulin or sulfonylureas, potential gallbladder disease, and the need for monitoring in patients with pre-existing diabetic retinopathy.

It is important to emphasise that Ozempic is not licensed for the treatment of fibromyalgia or any pain-related condition. Its use is strictly indicated for glycaemic control in type 2 diabetes. A higher-dose formulation of semaglutide (Wegovy) is separately licensed for weight management, but neither product is indicated for fibromyalgia. Any off-label use should be approached with caution and under specialist guidance.

Patients who experience side effects should report them to their healthcare professional or directly to the MHRA through the Yellow Card scheme (yellowcard.mhra.gov.uk).

Understanding Fibromyalgia: Symptoms and Current Treatments

Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties often referred to as 'fibro fog'. The condition affects approximately 2–4% of the UK population, with a higher prevalence in women than men. The exact cause of fibromyalgia remains unclear, but it is thought to involve abnormal pain processing in the central nervous system, leading to heightened sensitivity to pain signals.

Patients with fibromyalgia typically experience a constellation of symptoms beyond pain, including:

• Chronic widespread pain lasting at least three months, affecting multiple body regions

• Profound fatigue that is not relieved by rest

• Sleep disturbances, including non-restorative sleep and frequent waking

• Cognitive impairment, affecting concentration and memory

• Mood disorders, such as anxiety and depression

• Headaches, irritable bowel syndrome, and heightened sensitivity to temperature, light, and noise

Diagnosis is primarily clinical, based on patient history and examination, as there are no specific laboratory tests or imaging studies that confirm fibromyalgia. In UK practice, fibromyalgia is encompassed within the 'chronic primary pain' framework described in NICE Guideline NG193. Diagnosis involves excluding other conditions that might explain the symptoms, with basic investigations such as full blood count, inflammatory markers (ESR/CRP), thyroid function, and vitamin D levels often considered.

Current treatment approaches in the UK, as recommended by NICE, emphasise a multidisciplinary strategy. This includes patient education, exercise programmes (particularly aerobic and strengthening exercises), psychological therapies such as cognitive behavioural therapy (CBT), and consideration of a course of acupuncture or dry needling. Pharmacological interventions are more limited, with antidepressants such as duloxetine (a serotonin-noradrenaline reuptake inhibitor) or amitriptyline (a tricyclic antidepressant) sometimes considered. NICE advises against initiating gabapentinoids, opioids, paracetamol, NSAIDs, benzodiazepines, corticosteroids, and antipsychotics for chronic primary pain including fibromyalgia.

Red flags that require urgent medical attention include unexplained weight loss, fever, focal neurological deficits, or inflammatory joint swelling, as these may indicate alternative diagnoses requiring different management.

Potential Benefits and Risks of Ozempic for Fibromyalgia Patients

There is currently no official link or licensed indication for the use of Ozempic in the treatment of fibromyalgia. No robust clinical trials have been conducted specifically examining semaglutide's efficacy in managing fibromyalgia symptoms, and it is not included in any UK or international fibromyalgia treatment guidelines. However, some patients and clinicians have speculated about potential indirect benefits, particularly in fibromyalgia patients who also have comorbid obesity or metabolic syndrome.

Theoretical considerations include the fact that weight loss, which often occurs with Ozempic use, may reduce mechanical stress on joints and muscles, potentially alleviating some pain symptoms. Additionally, some researchers have hypothesised that chronic inflammation and metabolic dysfunction may play a role in fibromyalgia pathophysiology, though this remains an area of active investigation. While some preclinical studies suggest GLP-1 receptor agonists may have anti-inflammatory properties, it is important to emphasise that there is no clinical evidence demonstrating benefit in fibromyalgia patients.

Risks and considerations are significant. Ozempic carries a range of adverse effects that could be problematic for patients. Gastrointestinal side effects such as nausea, vomiting, and diarrhoea are common and may reduce quality of life. Other important safety considerations include risk of hypoglycaemia when combined with insulin or sulfonylureas, potential gallbladder disease, and the need for monitoring in patients with pre-existing diabetic retinopathy. The medication requires subcutaneous injection, which some patients may find challenging or anxiety-provoking.

From a safety and prescribing perspective, using Ozempic off-label for fibromyalgia would not be supported by current evidence and could expose patients to unnecessary risks without proven benefit. Patients with fibromyalgia who are considering Ozempic should only do so if they have a separate, licensed indication such as type 2 diabetes. Any such decision must be made in consultation with their GP or specialist, with careful consideration of individual circumstances, comorbidities, and potential drug interactions.

Evidence-Based Treatments for Fibromyalgia in the UK

The cornerstone of fibromyalgia management in the UK follows NICE Guideline NG193 on chronic pain, which recommends a holistic, patient-centred approach. Evidence-based treatments focus on improving function, reducing pain, and enhancing quality of life rather than seeking a cure, as fibromyalgia is a chronic condition requiring long-term management strategies.

Non-pharmacological interventions form the foundation of treatment:

• Exercise therapy: Aerobic exercise, strength training, and flexibility exercises have the strongest evidence base. Patients should start gradually and build up intensity to avoid symptom flare-ups. Programmes should be tailored to individual fitness levels and supervised where possible.

• Psychological therapies: Cognitive behavioural therapy (CBT) helps patients develop coping strategies, manage pain perception, and address associated anxiety and depression. Mindfulness-based stress reduction and acceptance and commitment therapy may also be beneficial.

• Patient education: Understanding the condition, setting realistic expectations, and learning self-management techniques are crucial for long-term outcomes.

• Acupuncture or dry needling: NICE suggests considering a course of these treatments for chronic primary pain.

Pharmacological options are more limited, with NICE advising caution:

• Antidepressants: A course of duloxetine, amitriptyline, citalopram, or other antidepressants may be considered after discussion of potential benefits and harms.

• NICE specifically advises against initiating the following medications for chronic primary pain (including fibromyalgia): antiepileptics (including gabapentinoids such as pregabalin and gabapentin), opioids, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, corticosteroids, and antipsychotics.

Any medication should be started at low doses with regular review of efficacy and tolerability.

When to seek medical advice: Patients should contact their GP if they experience new or worsening symptoms, significant functional impairment, or if current treatments are ineffective or causing intolerable side effects. Urgent medical attention is needed for red flags such as unexplained weight loss, fever, focal neurological deficits, or inflammatory joint swelling. Referral to specialist pain services, rheumatology, or multidisciplinary fibromyalgia clinics may be appropriate for complex cases. The NHS provides access to pain management programmes that combine physical, psychological, and educational components, offering comprehensive support for people living with fibromyalgia.

Frequently Asked Questions